Last updated: December 7, 2023
Sponsor: University of Florida
Overall Status: Completed
Phase
4
Condition
Inflammation
Treatment
CBD oil
Clinical Study ID
NCT05209867
IRB202101624 -A
OCR41346
Ages 21-60 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Willingness to take CBD and to participate in follow up for two months
- Older than 21 and younger than 60
- Under antiretroviral therapy for 5+ years and suppressed viral load (CD4 count <350cells/ml)
Exclusion
Exclusion Criteria:
- Conditions/medications that may impair the immune response, e.g., rheumatoidarthritis, cancer, diabetes, chronic infections, CAD (Cold agglutinin disease),cellulitis, autoimmune diseases such as lupus, sarcoidosis
- All medications that may affect inflammation such as aspirin, steroids, statins; CD4count <350cells/ml), pregnancy, and current marijuana or CBD use (urine drug screen)
- UF(University of Florida)/Shands staff and students will not be considered forenrollment
Study Design
Total Participants: 4
Treatment Group(s): 1
Primary Treatment: CBD oil
Phase: 4
Study Start date:
May 01, 2022
Estimated Completion Date:
December 12, 2022
Connect with a study center
University of Florida
Gainesville, Florida 32610
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.